GG
CUE icon

Gleason Group’s Cue Biopharma CUE Stock Holding History

Gleason Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.31K Hold
200
– – ﹤0.01% 287
2026
Q1 		$1.38K Hold
200
– – ﹤0.01% 214
2025
Q4 		$1.83K Hold
200
– – ﹤0.01% 208
2025
Q3 		$4.31K Hold
200
– – ﹤0.01% 177
2025
Q2 		$4.09K Hold
200
– – ﹤0.01% 182
2025
Q1 		$5.47K Hold
200
– – ﹤0.01% 177
2024
Q4 		$6.54K Hold
200
– – ﹤0.01% 179
2024
Q3 		$4.54K Hold
200
– – ﹤0.01% 178
2024
Q2 		$7.44K Hold
200
– – ﹤0.01% 204
2024
Q1 		$11.3K Hold
200
– – ﹤0.01% 170
2023
Q4 		$15.8K Hold
200
– – ﹤0.01% 160
2023
Q3 		$13.8K Hold
200
– – ﹤0.01% 172
2023
Q2 		$21.9K Buy
+200
New +$23.5K 0.01% 148

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gleason Group's CUE Position: Q2 2026 in Review

Gleason Group held its Cue Biopharma (CUE) position steady in Q2 2026 at 200 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

Gleason Group first reported a position in CUE in Q2 2023 and has held it in 13 quarters since. The position peaked at $21.9K in Q2 2023. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Gleason Group held 200 shares of Cue Biopharma worth $6.31K as of Q2 2026.
  • Gleason Group left its Cue Biopharma share count unchanged in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Gleason Group's portfolio in Q2 2026, its #287 holding.
  • Gleason Group first reported a position in Cue Biopharma in Q2 2023 and has held it in 13 quarters since.
  • Gleason Group's Cue Biopharma position peaked at $21.9K in Q2 2023.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Gleason Group's 13F filing for Q2 2026, filed 13 Jul 2026.